Here’s Why Dexcom (DXCM) Traded Down in Q3

In its third-quarter 2025 capitalist letter, Sands Capital Select Growth Strategy highlighted stocks specified arsenic DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is simply a aesculapian instrumentality institution that develops and commercializes continuous glucose monitoring (CGM) systems. The one-month instrumentality of DexCom, Inc. (NASDAQ:DXCM) was -8.29%, and its shares mislaid 19.94% of their worth implicit the past 52 weeks. On November 24, 2025, DexCom, Inc. (NASDAQ:DXCM) banal closed astatine $62.53 per share, with a marketplace capitalization of $24.52 billion.

Sands Capital Select Growth Strategy stated the pursuing regarding DexCom, Inc. (NASDAQ:DXCM) successful its 3rd 4th 2025 capitalist letter:

"DexCom, Inc. (NASDAQ:DXCM) is simply a starring shaper of glucose monitors for diabetes management. Shares declined during the quarter, pressured by broader weakness successful the aesculapian devices manufacture and heightened FDA and lawsuit scrutiny of merchandise reliability. Despite these outer pressures, Dexcom continues to execute good pursuing its mid-2024 operational challenges. The 2nd 4th marked its 3rd consecutive 4th of accelerating twelvemonth over-year gross growth, supported by near-record caller diligent additions. While absorption raised 2025 gross guidance, the summation was much cautious than statement expected, disappointing investors. We judge this blimpish stance creates country for upside successful the 2nd fractional of 2025. Dexcom ended the 4th trading adjacent its all-time debased guardant net multiple, which we presumption arsenic a disconnect from its maturation outlook. Potential catalysts see beardown adoption of its recently launched 15 time sensor, expanded Medicare sum for type-2 non insulin patients, and clarity connected the company's long-range plan. We expect borderline leverage from the 15-day sensor should besides lend meaningfully to profitability successful 2026."

DexCom, Inc. (NASDAQ:DXCM) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 60 hedge money portfolios held DexCom, Inc. (NASDAQ:DXCM) astatine the extremity of the 2nd quarter, the aforesaid arsenic successful the erstwhile quarter. For the 3rd 4th of 2025, DexCom, Inc. (NASDAQ:DXCM) reported global revenue of $1.21 billion, compared to $994 cardinal successful the 3rd 4th of 2024. While we admit the imaginable of DexCom, Inc. (NASDAQ:DXCM) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.